NAD+ Infusions in Luxury Rehab
Biochemical buzzword as high-ticket detox
NAD+ (nicotinamide adenine dinucleotide) is a genuine and important coenzyme involved in cellular energy production and numerous metabolic processes. Private rehab clinics have seized on this legitimate biochemistry to market NAD+ intravenous infusions as addiction treatment—at premium prices. The gap between the basic science and the clinical claims is substantial.
The Science vs. The Claims
NAD+ levels do decline with age, and the molecule is genuinely important for metabolism. Research on NAD+ precursors (like NMN and NR) in animal models has shown some promising results for aging-related conditions. But the leap from "NAD+ is important" to "IV NAD+ infusions treat addiction" involves claims that far outstrip the evidence.
Clinical trials specifically testing NAD+ infusions for addiction are sparse and of limited quality. The claimed mechanisms—reducing cravings, repairing neurological damage, accelerating detox—are biologically plausible but unproven in rigorous human studies.
Why It Matters for Luxury
NAD+ infusions exemplify how legitimate science can be stretched to support premium products. The biochemistry is real; the extrapolation to clinical benefit is marketing. For desperate families seeking addiction treatment, the scientific vocabulary provides reassurance that may not be warranted. The luxury health market's tolerance for evidence-light interventions is particularly concerning when patients are vulnerable.
News & Coverage
- NAD+ Infusion: \"We Just Don't Know If There's Any Benefit\" — CNBC reports longevity doctors remain skeptical; IV NAD+ appears to be rapidly cleared from body with minimal tissue uptake — March 2025
- FDA Warning: Injectable NAD+ Products May Be Unsafe — FDA warns some injectable NAD+ products made with non-sterile food-grade ingredients; reports of severe chills, vomiting, and shaking — April 2024
- NAD+ Can Directly Enter Cells: Groundbreaking Study — Research reveals intact NAD+ molecules can pass through specialized channels, changing understanding of supplementation mechanisms — December 2023
- NAD+ Therapy Market Reaches $745 Million — Market grows despite limited clinical evidence; wellness clinics worldwide now offer NAD+ drips alongside vitamin infusions — December 2025
Research
-
What Is Really Known About the Effects of Nicotinamide Riboside Supplementation in Humans — June 2024
Pencina KM, Lavu S, Dos Santos M, et al. Science Advances, 10(11), eadi4862, 2024. DOI: 10.1126/sciadv.adi4862This critical review of 25 published human trials found that oral NAD+ precursor supplementation has displayed "few clinically relevant effects" and identified "an unfortunate tendency in the literature to exaggerate the importance and robustness of reported effects." This directly challenges marketing claims made by NAD+ infusion clinics.
-
Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults — April 2018
Martens CR, Denman BA, Mazzo MR, et al. Nature Communications, 9, 1286, 2018. DOI: 10.1038/s41467-018-03421-7This randomized crossover trial demonstrated that oral NAD+ precursors are safe and can elevate blood NAD+ levels in older adults. However, the study found only trends toward reduced blood pressure and arterial stiffness—not the dramatic anti-aging effects often marketed. The gap between "elevates NAD+" and "produces clinical benefit" remains unproven.
-
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions — September 2023
Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Journals of Gerontology: Series A, 78(12), 2435-2448, 2023. DOI: 10.1093/gerona/glad207This comprehensive review found that while NAD+ precursor supplementation is safe and can increase NAD+ levels, "it is still unclear whether supplementation can enhance physiological function and improve key clinical outcomes." The authors note that small sample sizes and heterogeneous protocols limit meaningful interpretation—concerns especially relevant to IV NAD+ protocols at wellness clinics.